TriNetX® will continue to support all existing Zetta Genomics customers utilizing the award-winning XetaBase® technology for research and patient care innovation CAMBRIDGE, Mass. and CAMBRIDGE, United ...
With more than 2,000 citations and year-over-year growth nearing 80%, TriNetX outpaces competitors and fuels high-impact science published in top medical journals. CAMBRIDGE, Mass., Oct. 15, 2025 ...
Regeneron has exclusive opportunity to connect large-scale genomic and proteomic data cohorts to TriNetX’s industry-leading global network of electronic health record data Collaboration will expand ...
Partnership taps real-world data to accelerate clinical trials, research, and drug development in Japan. CAMBRIDGE, Mass., Feb. 12, 2025 /PRNewswire/ -- TriNetX, a global leader in real-world data ...
Real-world data (RWD), artificial intelligence (AI), and patient-centric trial design lead pharma priorities in 2025, but data compatibility, regulatory hurdles, and security concerns threaten to ...
The MarketWatch News Department was not involved in the creation of this content. TriNetX(R) will continue to support all existing Zetta Genomics customers utilizing the award-winning XetaBase(R) ...
The MarketWatch News Department was not involved in the creation of this content. TriNetX(R) will continue to support all existing Zetta Genomics customers utilizing the award-winning XetaBase(R) ...
Zetta's flagship platform, XetaBase, is a multiomic capture and analytics platform designed for population-scale genomic analysis. XetaBase is currently in use by leading healthcare provider ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results